Diabetes Updates最新文献_第2页

Type 2 diabetes mellitus (T2DM) and intestinal microbiota 2型糖尿病(T2DM)与肠道菌群

Diabetes Updates Pub Date : 1900-01-01 DOI: 10.15761/du.1000154

T. Ohara

引用次数: 0

Sarcopenia reversible by diet 肌肉减少症可通过饮食逆转

Diabetes Updates Pub Date : 1900-01-01 DOI: 10.15761/du.1000133

H. Gao-Balch Y

引用次数: 0

Knowledge and self-care in diabetes mellitus and their correlations with sociodemographic, clinical and treatment variables 糖尿病患者的知识和自我保健及其与社会人口学、临床和治疗变量的关系

Diabetes Updates Pub Date : 1900-01-01 DOI: 10.15761/du.1000145

Moraes Nm, Souza Gfp, Brito Fi, Antonio Júnior Me, Cipriano Ae, Costa Nsv, Rezende Tm, S. Aj, Gomes Lc

引用次数: 1

Empagliflozin in paroxysmal or persistent atrial fibrillation: a possible antiarrhythmic effect 恩格列净治疗阵发性或持续性房颤:可能的抗心律失常作用

Diabetes Updates Pub Date : 1900-01-01 DOI: 10.15761/du.1000151

F. G, S. P

{"title":"Empagliflozin in paroxysmal or persistent atrial fibrillation: a possible antiarrhythmic effect","authors":"F. G, S. P","doi":"10.15761/du.1000151","DOIUrl":"https://doi.org/10.15761/du.1000151","url":null,"abstract":"Background: Many studies have highlighted an increased risk of developing atrial fibrillation (AF) in diabetic patients. The SGLT2 inhibitors, in addition to glycaemic control, have shown pleiotropic effects on the cardiovascular system, proving to be particularly advantageous in patients with heart failure. In this study we evaluated a group of patients with paroxysmal AF (PAF) or persistent AF (PeAF) affected by type 2 diabetes and treated with empagliflozin. Methods: This is a case-crossover study obtained from our database of patients affected by PAF or PeAF. We extracted 23 consecutive subjects ICD wearers and affected by diabetes that started treatment with empagliflozin during the follow-up. Results: All enrolled patients were ICD wearers because at high risk of sudden cardiac death and received amiodarone; empagliflozin was added during follow-up for the treatment of diabetes. We evaluated the recurrence of PAF and the days free from AF one year before and one year after starting treatment with empagliflozin. The recurrence of AF was significantly lower after starting empagliflozin than before the treatment (p: 0.001). Conclusion: Our data suggest that empagliflozin is able to reduce the recurrences of AF in diabetic patients with PAF or PeAF. Further studies might demonstrate an antiarrhythmic effect of empagliflozin and change the therapeutic approach in subjects at high risk of AF.","PeriodicalId":309709,"journal":{"name":"Diabetes Updates","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126390555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Best anthropometric predictors of fasting blood sugar, prediabetes, and diabetes 最好的人体测量预测空腹血糖，前驱糖尿病和糖尿病

Diabetes Updates Pub Date : 1900-01-01 DOI: 10.15761/du.1000149

I. Yakubu, Y. Kaoje, Tahoma Jabbe, Aliyu Abdullahi Abubakar

{"title":"Best anthropometric predictors of fasting blood sugar, prediabetes, and diabetes","authors":"I. Yakubu, Y. Kaoje, Tahoma Jabbe, Aliyu Abdullahi Abubakar","doi":"10.15761/du.1000149","DOIUrl":"https://doi.org/10.15761/du.1000149","url":null,"abstract":"Background: The association between obesity and type 2 diabetes is well-known. The measure of obesity that best predicts fasting blood sugar levels remains a subject of debate. The objective of the study was to determine the best anthropometric predictor of FBS, prediabetes, and diabetes among apparently healthy bank workers in Nigeria. Methods: This study analyzed dataset of a cross-sectional survey of apparently healthy 1191 bank workers in 18 state capitals across the six geopolitical regions of Nigeria. The dataset was processed and analyzed with SPSS. Correlation and discriminant analysis were performed to determine the best anthropometric predictors of FBS, prediabetes, and diabetes. Results: The 1191 subjects were aged 22-59 years old, 80.2% were males, and 19.8% females. The average FBS was 5.2 ± 1.2 mmol/l, BMI 26.7 ± 4.6 kg/m 2 , WC 80.1 ± 25.1 cm, HC 88.9 ± 26.7 cm, WHR 0.9 ± 0.09, and WHtR 0.47 ± 0.15. The prevalence of diabetes was 4%, prediabetes 7%, overweight 42%, and obesity 23%. The best anthropometric predictor of FBS was WC (r=0.231, p<0.0001), while the best predictor of diabetes was WHR (AUC 0.64, 95% CI 0.55-0.73) and HC for prediabetes (AUC 0.64, 95% CI 0.58-0.69). The best predictors of all the three outcomes combined were WC and WHtR at cut-off values of 87 cm and 0.5 in both sexes. Conclusions: Both WC and WHtR at cut-off values of 87 cm and 0.5 are appropriate as discriminative anthropometric indices for both prediabetes and diabetes in both sexes. The finding of HC as the best predictor of prediabetes calls for further research in this direction.","PeriodicalId":309709,"journal":{"name":"Diabetes Updates","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127116466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

A dipeptidyl peptidase inhibitor, evogliptin, directly prevents nephrin loss and podocyte damage via post-transcriptional regulation 一种二肽基肽酶抑制剂，乙酰格列汀，通过转录后调控直接防止肾素丢失和足细胞损伤

Diabetes Updates Pub Date : 1900-01-01 DOI: 10.15761/du.1000139

Cheong Yh, H. Park, Jung Ih, Chae Yn, Kim Th, Lee Br, Kim Mk

{"title":"A dipeptidyl peptidase inhibitor, evogliptin, directly prevents nephrin loss and podocyte damage via post-transcriptional regulation","authors":"Cheong Yh, H. Park, Jung Ih, Chae Yn, Kim Th, Lee Br, Kim Mk","doi":"10.15761/du.1000139","DOIUrl":"https://doi.org/10.15761/du.1000139","url":null,"abstract":"Background: Loss of podocytes due to podocyte damage leads to impairment of renal filtration function, thereby bringing about proteinuria in glomerular diseases. Dipeptidyl peptidase 4 (DPP4) inhibitors are reported to protect against podocyte damage in preclinical animal models. However, the direct effects of DPP4 inhibitors on podocytes are not yet fully understood. Methods: Streptozotocin-induced diabetic mice and db/db mice were provided with evogliptin, linagliptin, or irbesartan for 12 weeks. Mouse and human podocytes were treated for 72 h and cell lysate and medium were analyzed. Results: In diabetic mice with renal impairment, evogliptin treatment was more efficacious than linagliptin in blocking urinary nephrin excretion, with preserved renal nephrin and phospho-nephrin levels observed regardless of glucose control. In differentiated murine podocytes and primary human podocytes, evogliptin also outperformed linagliptin in preserving nephrin protein levels under high glucose and angiotensin II conditions that mimicked diabetic nephropathy conditions. Intriguingly, after 72 h of treatment, evogliptin effectively blocked the increase in cellular DPP4 activity without altering DPP4 expression levels, while linagliptin did not. Blocking protein synthesis or clathrin-mediated endocytosis eliminated the nephrin-preserving effects of evogliptin, but nephrin gene expression was not altered by any treatments, suggesting potential post-transcriptional regulation. In podocytes, evogliptin directly reduced the stress-induced cellular signals, pro-apoptotic protein cleavage and shedding of membrane DPP4 that increased under diabetic nephropathy-mimicking conditions. Conclusions: Our findings suggest a direct protective effect of evogliptin against podocyte damage through maintenance of nephrin levels, alleviation of stress responses and a reduction in apoptotic cell death.","PeriodicalId":309709,"journal":{"name":"Diabetes Updates","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132504024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

On the mechanisms of endogenous synthesis of xanthurenic acid a possible cause of human diabetes mellitus 黄嘌呤酸内源性合成机制的探讨——一种可能引起人糖尿病的物质

Diabetes Updates Pub Date : 1900-01-01 DOI: 10.15761/du.1000120

Meyramov Gg, Meyramova-Abdraimova Ag, Shaybek As

引用次数: 0

Religion's impact on Ramadan fasting for patients with diabetes mellitus: A review of evidence 宗教对糖尿病患者斋月禁食的影响:证据综述

Diabetes Updates Pub Date : 1900-01-01 DOI: 10.15761/du.1000143

Imad R. Musa

{"title":"Religion's impact on Ramadan fasting for patients with diabetes mellitus: A review of evidence","authors":"Imad R. Musa","doi":"10.15761/du.1000143","DOIUrl":"https://doi.org/10.15761/du.1000143","url":null,"abstract":"Introduction: Ramadan is the holy moon month for Muslims during which they fast from predawn to after sunset. Ramadan is a divine duty for all healthy Muslim adults. There is a large number of Muslims with type 2 diabetes mellitus, who have the low-to-moderate risk that is associated with fasting. Aim: This study aims to explore the role of the Islamic religion in promoting safe Ramadan fasting for Muslim patients of diabetes mellitus. Method: A systematic search of studies relating to diabetes mellitus during Ramadan fasting was conducted between the 1st of January 1990 and the end of February 2019 for relevant studies, using the following databases: PubMed and Google search engine. The words “religious”, “fasting”, “Ramadan” and “diabetes mellitus were used. Result: A total of 153 citations were initially identified. One hundred four were removed for failing to address the aim of the study, duplication, lack of proper citation, and poor use of language. After screening titles and abstracts, 49 full-text articles were retrieved for eligibility analysis. Nine studies focused on the importance and positive effects of religion on fasting for these patients, fifteen studies concentrated on the exemptions during Ramadan, six studies evaluated the reasons for fasting among exempted persons, seven studies corrected some wrong ideas about fasting, religious education (five studies) (lack of knowledge and its importance) and the effect of cooperation between religion scholars and healthcare providers (thirteen studies). Six studies covered more than one item. Conclusion: Islamic religious teachings and medical recommendations can strengthen each other to promote safe adherence to divine duty for patients with diabetes mellitus during Ramadan. *Correspondence to: Imad eddin Rahamtalla Musa, Royal Commission Hospital at Jubail Industrial City, P.O.B. 11994, zip code 31961, KSA, E-mail: irthesudanese@hotmail.com","PeriodicalId":309709,"journal":{"name":"Diabetes Updates","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128899214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sulfonylureas as treatment choice in Diabetes Mellitus : Where are we now? 磺脲类药物作为糖尿病的治疗选择:进展如何?

Diabetes Updates Pub Date : 1900-01-01 DOI: 10.15761/DU.1000124

Manta A, Peppa M

引用次数: 1

Forskolin alleviates diabetic nephropathy via inhibition of aldose reductase and advanced glycation end products formation 福斯可林通过抑制醛糖还原酶和晚期糖基化终产物的形成来减轻糖尿病肾病

Diabetes Updates Pub Date : 1900-01-01 DOI: 10.15761/du.1000127

S. Damera, Ajmera Rr, Ciddi

{"title":"Forskolin alleviates diabetic nephropathy via inhibition of aldose reductase and advanced glycation end products formation","authors":"S. Damera, Ajmera Rr, Ciddi","doi":"10.15761/du.1000127","DOIUrl":"https://doi.org/10.15761/du.1000127","url":null,"abstract":"Objectives: Various mechanisms including polyol pathway along with a complex integrating paradigm with Aldose reductase (AR) and advanced glycation end products (AGE) formation have been implicated in the pathogenesis of diabetic nephropathy. Methods: The present study was aimed at investigating a well-known antioxidant, Forskolin for its therapeutic role in streptozotocin-induced diabetic nephropathy in rats. The effect of Forskolin was investigated by assessing the key markers of kidney function along with the morphological changes in the kidney. Further, the effect of Forskolin on the formation of AGEs and AR inhibition and lipid peroxidation was compared with that of a standard AR inhibitor, fidarestat. Results: The results revealed that Coleus forskohlii methanolic extract and Forskolin significantly (P<0.05) decreased the blood glucose levels, urinary protein excretion, serum creatinine and blood urea nitrogen in diabetic rats. Administration of Forskolin to diabetic rats decreased kidney lipid peroxides and nitrate levels along with decrease in AGEs formation. In addition, Forskolin was found to inhibit kidney AR activity. Conclusion: Thus, the results obtained in this study underline the potential of Forskolin as a possible therapeutic agent against diabetic complications such as nephropathy. *Correspondence to: Ciddi Veeresham, Professor of Pharmacy, University College of Pharmaceutical Sciences, Kakatiya University, Warangal, Telangana, India 506009, E-mail: ciddiveereham@yahoo.co.in","PeriodicalId":309709,"journal":{"name":"Diabetes Updates","volume":"56 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134603697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0